OIS@ASRS

B+L Shares Developments in Vitrectomy

By Mario Admin | August 29, 2016

Vitrectomy technology has changed little since Robert Machemer, MD, invented his 17-gauge single-port pneumatic cutter in 1972, Bausch + Lomb senior VP and chief medical…

Read More

Where Private Financing in Health Care Is Headed

By Mario Admin | August 29, 2016

In the large world of private funding in health care, ophthalmology pales in comparison with huge sectors like oncology and cardiovascular, but ophthalmology has had…

Read More

Funding Companies in Today’s Volatile Market

By Mario Admin | August 29, 2016

US financial markets had “the worst 10-day start for Wall Street in history” in January 2016, said Andrew Gitkin, managing director and head of West…

Read More

Pfenex Moves Forward with Lucentis Biosimilar

By Mario Admin | August 29, 2016

The lead-up to OIS@ASRS had been eventful for biotech company PFEnex, as Hubert C. Chin, MD, chief medical officer, reported to the “Paying for Breakthrough…

Read More

AGTC Pursues Gene Therapy on Multiple Tracks

By Mario Admin | August 29, 2016

AGTC is pursuing six different genetic treatments for four different retinal diseases, and expects to have clinical data from its Phase I trial of its…

Read More

Regeneron: Pursuing Combination Therapies with PDGFR-beta and Ang2

By Mario Admin | August 29, 2016

Regeneron Pharmaceuticals Inc. markets the highly successful anti-VEGF injection EYLEA (aflibercept), which is FDA approved for neovascular (wet) age-related macular degeneration (AMD), macular edema following…

Read More

Aerpio Therapeutics: Focus on Tie2 Activation

By Mario Admin | August 29, 2016

Aerpio Therapeutics is focused on the development of novel therapeutics for vascular disorders, with a concentration on eye diseases. Joseph Gardner, CEO of Aerpio, provided…

Read More

Allegro Ophthalmics: First-in-Class Anti-Integrin Agent

By Mario Admin | August 29, 2016

Allegro Ophthalmics is developing Luminate, a first-in-class anti-integrin peptide with a novel mechanism of action for both anti-angiogenesis and vitreolysis. The company is in late-stage…

Read More

Opthea: Targeting a More Complete Blockade of VEGF

By Mario Admin | August 26, 2016

Opthea, a public company listed on the Australian Stock Exchange, is developing OPT-302, a novel therapy for wet age-related macular degeneration (AMD). The company’s lead…

Read More

Retina Experts Serve Up a Combination Platter at OIS@ASRS

By Mario Admin | August 26, 2016

Contributed By: Michael Lachman The OIS@ASRS panel discussion on Emerging Approaches to Combination Therapies in AMD & DME was moderated by Mark Humayan, MD, PhD,…

Read More

Where Will Imaging Take Retina Treatments?

By Mario Admin | August 25, 2016

William J. Link, PhD, managing director of Versant Ventures, gathered the leaders in imaging to outline what’s ahead for retina. Participants were Ralf Kuschnereit, PhD,…

Read More

How Do Strategics View Retina Opportunities?

By Mario Admin | August 18, 2016

Retinal disease remains a challenging target for drug and device makers, but a panel of senior executives at last week’s OIS@ASRS says the potential benefits…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.